Final count down to HFA albuterol inhalers: Are we ready as yet?

Clinical Pediatrics

Volumn 48, Issue 2, 2009, Pages 131-134

  Butt, Ahmed T ^a,b   Kamat, Deepak ^a   Pansare, Milind ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; LEVALBUTEROL; PROCATEROL; PROPELLANT; SALBUTAMOL; SALBUTAMOL SULFATE;

ASTHMA; CANDIDIASIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSPHONIA; ENVIRONMENTAL IMPACT; HUMAN; METERED DOSE INHALER; NOTE; PARTICLE SIZE;

ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHLOROFLUOROCARBONS; HUMANS; HYDROCARBONS, FLUORINATED; METERED DOSE INHALERS; OZONE; PATIENT EDUCATION AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 59349108307     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922808327322     Document Type: Note

References (16)

1. US Food and Drug Administration. Questions and answers on final rule of albuterol MDIs. www.fda.gov/cder/mdi/mdifaqs.htm. Updated may 30, 2008. Accessed October 15, 2008.
2. Leo HL, Dombkowski KJ, Clark NM The economic effect of the hydrofluoroalkane albuterol transition on children with asthma. J Allergy Clin Immunol. 2008 ; 121: 776-777.
3. Boyd A. FDA: Patients should switch to HFA inhalers. www.efluxmedia.com/ news-FDA-Patients-Should-Switch-to-HFA-Inhalers-18415.html. Published June 2, 2008.
4. Finegold I. Eliminating CFC-albuterol. www.epocrates.com/company/news/ 050808.html. Accessed October 15, 2008.
5. Dolivich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest. 2005 ; 127: 335-371.
6. Leach CL The CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005 ; 50: 1201-1206.
7. US Environmental Protection Agency. Benefits of the CFC phaseout. http://epa.gov/Ozone/geninfo/benefits.html. Accessed October 15, 2008.
8. Wysowski DK, Swan J. Use of inhalant medications with and without chlorofluorocarbon propellants in the United States, 1996-2000. J Allergy Clin Immunol. 2002 ; 110: 51-53.
9. Alternative Fluorocarbons Environmental Acceptability Study. Montreal Protocol on Substances that Deplete the Ozone Layer. http://afeas.org/montreal- protocol.html. Updated June 2, 2006. Accessed October 15, 2008.
10. Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. J Allergy Clin Immunol. 1999 ; 106: 221-226.
11. Clark A. The physics of aerosol formation by MDIs: limitations of the current approach. J Biopharm Sci. 1992 ; 3: 69-76.
12. Lumry W., Noveck R., Weinstein S., et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Allergy Asthma Immunol. 2001 ; 86: 297-303.
13. Ramsdell JW, Klinger NM, Ekholm BP, Colice GL Safety of long-term treatment with HFA albuterol. Chest. 1999 ; 115: 945-951.
14. Leach C. Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999 ; 104: 250-252.
15. Tashkin DP Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered dose inhalers. Chest. 1999 ; 115: 316-318.
16. Borgstrom L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol. 1999 ; 104: 246-249.